ACS Medicinal Chemistry Letters · 2018 · 76 citations · 10 references
PharmacyMedicinal ChemistryPharmacologyCancer PharmacologyDrug DesignDrug DiscoveryBreast Cancer PharmacotherapyHormonal Cancer TherapyHormonal TherapyOncology PharmacologyPotency OptimizationBreast Cancer Endocrine TherapyEr-associated DegradationEstrogen PharmacologyEstrogen Receptor SignalingHormone Receptor - Positive Breast CancerHormone Receptor ModulationHormone Receptor-positive Breast Cancer TherapySide Chain Substitution
The further optimization of ER-α degradation efficacy of a series of ER modulators by refining side-chain substitution led to efficacious selective estrogen receptor degraders (SERDs). A fluoromethyl azetidine group was found to be preferred and resulted in the identification of bis-phenol chromene 17ha. In a tamoxifen-resistant breast cancer xenograft model, 17ha (ER-α degradation efficacy = 97%) demonstrated tumor regression, together with robust reduction of intratumoral ER-α levels. However, despite superior oral exposure, 5a (ER-α degradation efficacy = 91%) had inferior activity. This result suggests that optimizing ER-α degradation efficacy leads to compounds with robust effects in a model of tamoxifen-resistant breast cancer. Compound 17ha (GDC-0927) was evaluated in clinical trials in women with metastatic estrogen receptor-positive breast cancer.
10
Ashini L. Wijayaratne, Donald P. McDonnell · Journal of Biological Chemistry · 2001 · 422 citations · Full text
Peptide Antagonists of the Human Estrogen Receptor
John D. Norris, Lisa A. Paige, Dale J. Christensen et al. · Science · 1999 · 377 citations
Estrogen Receptors as Therapeutic Targets in Breast Cancer
Eric A. Ariazi, Jennifer L. Ariazi, Fernando Cordera et al. · Current Topics in Medicinal Chemistry · 2006 · 250 citations
Medicine, Oncology, Pharmacology +16
Andiliy Lai, Mehmet Kahraman, Steven P. Govek et al. · Journal of Medicinal Chemistry · 2015 · 247 citations · Full text
Medicine, Oncology, Pharmacology +13